ArgMatrix | Pharmaceutical Grade L-Arginine

LABORATORY PROCESSING
& MANUFACTURING of L-ARGININE BAAR

ARGMATRIX™

L-ARGININE BAAR TRANSPORT
Nanoparticle Biostrategy

CREATING SAFE L-ARGININE
FORMULAS IN HUMANS

CERTIFIED NITRIC OXIDE
VEGETARIAN FORMULA

NUTRILAB CORPORATION FLOW CHART
for PROCESSING L-ARGININE
WITH A BLIND AMINO ACID RIDER

NANO & PICO TECHNOLOGY

PRODUCTION OF PHARMACEUTICAL GRADE L-ARGININE-BAAR
(L-Arginine with a Blind Amino Acid Rider)

As for all currently identified amino acids, fermentation is controlled by regulating pH near the neutral point.

Due to the high oxygen requirements, the L-Arginine-BAAR undergoes advanced purification.

Advanced purification methods are necessary to obtain pure Pharmaceutical Grade L-Arginine from fermentation.

SOURCE OF AMINO ACIDS

SOURCE: Natural starches from tapioca and organic corn

PRODUCTION METHOD

1)	Fermentation: The starches are hydrolyzed with natural enzymes (liquid amylase and glucoamylase) to form a liquid. After filtration, the solution is analyzed against the standard. The partial pressure of oxygen in the liquid is determined constantly by an automatic oxygen analyzer. Cell respiration rate is calculated by measuring the partial pressure of oxygen in the effluent gas. Quantitative evaluation of oxygen transfer during the fermentation is utilized.
2)	Isolation and Purification: After the fermentation process is completed, microorganisms are separated by centrifugal separation and/or membrane filtration. The supernatant is charged to a resin column to separate organic acids or other amino acids. After filtration through active carbon powder, the filtrate is concentrated to form L-arginine crystals, which are separated via centrifugation. The crystals are dissolved in pure water and then ultrafiltered. The pure crystals are dissolved by concentration and cooling.
3)	Cooling: The concentrated solution is cooled to ~ 10 degrees C to obtain amino acid crystals. The crystals are dried with a dryer to minimize moisture. The obtained amino acid crystals are 98.5 % pure Pharmaceutical Grade L-Arginine (PGLA). The PGLA crystals are then assayed and Elemental L-arginine levels are quantified.

ARGMATRIX™ FLOW CHART

FERMENTATION: Certified Vegetarian formula. No animal sources or derivatives.

STARCHES HYDROLYZED with natural enzymes

CENTRIFUGAL SEPARATION

CONCENTRATION

2nd CENTRIFUGAL SEPARATION

COOLING & DRYING

ATTACHMENT of BLIND AMINO ACID RIDERS

NITRIC OXIDE (NO)
DEPENDENT PATHWAYS

Creation of any Nitric Oxide (NO) formula requires targeting NO dependent pathways, which have been scientifically and medically proven to be a valuable therapeutic approach in the utilization of NO in humans.

In response to physiological stimulation, for example in endothelial cells and neurones, NO is generated rapidly and transiently at low (picomolar)(Pico-Size) concentrations.

NO’s solubility and diffusion properties closely resemble those of oxygen, and like oxygen, it is a gas under atmospheric conditions but a solute in biological systems.

In the immune system, Nitric Oxide evolved as a toxic molecule in innate defense, but in humans, its actions evolved to include immune regulation.

Avoiding the potential toxic qualities of Nitric Oxide (NO) requires utilization of Blind Amino Acid Riders, which negate the toxic properties of NO.

BIOCHEMICAL ATTACHMENT
OF BLIND AMINO ACID RIDERS:

CREATION OF BLIND AMINO
ACID RIDERS

L-Arginine and Nitric Oxide formulas require a Blind Amino Acid Rider in order to render the L-Arginine safe for humans long term.

L-Arginine without a Blind Amino Acid Rider has been proven to cause death in ~ 10 percent of the people who ingested L-Arginine (Johns Hopkins University – published in the Journal of the American Medical Association (JAMA) journal).

Creation of the Blind Amino Acid Riders (BAAR) involves an extremely complicated and timely 32-step Proprietary process developed by Dr. Ann de Wees Allen®, therefore the process for the production of BAAR is not published*.

*	Nutrilab Corporation is currently the only company licensed to produce BAAR’s for L-Arginine, Nitric Oxide, Growth Hormone, and Anti-Aging formulas.

Once the BAAR (minuscule glycoside slurry) has been produced in the laboratory, they are attached to the L-Arginine molecules that have been fermented, isolated, and cooled.

L-Arginine cannot cross the Blood Brain Barrier (BBB) without a Blind Amino Acid Rider, thus formulas that do not contain a BAAR do not successfully cross the BBB, and do not elicit a Growth Hormone/Anti-Aging response in humans.

The Blind Amino Acid Rider allows transport of the L-arginine molecules across the Blood-Brain-Barrier (BBB) in humans.

This requires that the Blind Amino Acid Rider is manufactured at the Nanoscale (www.EdibleComputerChips.com) and Picoscale.

In its neuroprotective role, the Blood-Brain-Barrier (BBB) blocks agents from entering the brain.

Allowing therapeutic agents to cross the BBB without allowing dangerous agents access to the delicate brain-balance is a very intricate process involving many years of specialized research.

In a Tertiary Attachment Process, the L-arginine molecules (as processed herein) are biochemically attached to the BAAR (minimizing heat contact).

This allows the L-Arginine-BAAR to access the Blood-Brain-Barrier, as a “brain-friendly” agent, during Delta Sleep Cycle.

ENDOTHELIAL-CELL-GAPS

The specific and delicate proprietary extraction process is required to produce the Blind Amino Acid Riders that attach to an amino acid molecule, and transport it safely over the Blood-Brain-Barrier.

The BAAR Nanoparticles possess a diameter small enough to penetrate through diminutive capillaries into the cell's internal machinery to create a pre-programmed response.

BAAR facilitates access through endothelial-cell-gaps.

These gaps allow soluble BAAR to pass into the blood stream, where it is carried throughout the body, and subsequently passed out of the blood into different tissues.

In the brain, these endothelial cells are packed more tightly together, due to the existence of zonulae occludentes (tight junctions) between them, blocking the passage of most molecules.

L-ARGININE TRANSPORT:
Nanoparticle Biostrategy

Only a Specific Transport System of BAAR will allow the amino acid L-arginine to cross the Blood-Brain-Barrier.

The BAAR acts as a Carrier-Mediated-Transporter (CMT) for the amino acid L-arginine, with specific function in Nanoparticle biostrategy designed to allow transport across the Blood-Brain-Barrier.

REVERSE ENGINEERING

The L-ARGININE BAAR 32-step bioengineering process defies reverse-engineering.

It is currently impossible to “copy” or duplicate the BAAR Nanotechnology due to the minuscule size and complexity of the process and components used in the development process.

Thus, L-ARGININE BAAR and ARGMATRIX™ cannot be reverse engineered or copied.

www.NUTRILABUSA.com

THIS DOCUMENT MAY NOT BE COPIED

UNDER FEDERAL TRADEMARK & COPYRIGHT LAWS